Design of the β3-adrenergic agonist treatment in chronic pulmonary hypertension secondary to heart failure trial
Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve p...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:10230/45260 |
| Acceso en línea: | http://hdl.handle.net/10230/45260 http://dx.doi.org/10.1016/j.jacbts.2020.01.009 |
| Access Level: | acceso abierto |
| Palabra clave: | CCT Cardiac computed tomography CMR Cardiac magnetic resonance CpcPH Combined pre - and post - capillary pulmonary hypertension ECG Electrocardiography Heart failure Intention to treat Isolated post-capillary pulmonary hypertension Left heart disease Left ventricular Left ventricular ejection fraction N-terminal prohormone of brain natriuretic peptide New York Heart Association Pulmonary artery pressure Pulmonary hypertension Per protocol Pulmonary vascular resistance Right ventricle Adrenoreceptors Cyclic guanosine monophosphate Imaging Treatment Beta-3 adrenoreceptor |
| Sumario: | Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]; NCT02775539). |
|---|